bristol myers squibb
Bristol-Myers Squibb Reacquires Rights To ASLAN Drug
Bristol-Myers Squibb will be reacquiring the rights to ASLAN002, a gastric and breast cancer drug, for several APAC markets.
GIS & Pryobett To Develop Pyrosequencing For Clinical Diagnostics
The novel pyrosequencing platform can perform real-time sequencing for quicker medical decision-making.
BMS Foundation Awards US$3.5 Million In Hepatitis Grants
Bristol-Myers Squibb has awarded US$3.5 million in grants to tackle the 'silent epidemic' of hepatitis in India and China.
Bristol-Myers Squibb, Kyowa Hakko Kirin To Commercialize Coniel In China
Bristol-Myers Squibb and Kyowa Hakko Kirin will commercialize Coniel, a calcium channel blocker for the treatment of hypertension and angina pectoris, in China.
Samsung BioLogics To Manufacture Antibody Drug For Bristol-Myers Squibb
Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its Songdo Incheon plant in South Korea.
BMS, Simcere Pharma To Co-Develop Orencia® SC In China
BMS and Simcere will co-develop and co-commercialize the subcutaneous formulation of Orencia® for the treatment of rheumatoid arthritis in China.
Bristol-Myers Squibb Awards Four Grants For Hepatitis Education
To mark World Hepatitis Day 2012, the Bristol-Myers Squibb Foundation has awarded four new grants focused on Hepatitis B and Hepatitis C research in China and India.
Bristol-Myers Squibb And Tsinghua University Enter Research Partnership
Bristol-Myers Squibb Company and Tsinghua University of Beijing, China, announced this Monday the formation of a multi-year research partnership.
Bristol-Myers Squibb To Support Hepatitis B, C Research In Asia
The Bristol-Myers Squibb Foundation has awarded three new grants to further research into hepatitis B and C in China and India.
Simcere Pharma & BMS To Develop CETP Inhibitor BMS-795311
BMS and Simcere Pharma have agreed to co-develop BMS-795311, a preclinical small molecule inhibitor of the cholesteryl ester transfer protein.
